Header Logo

Connection

WAYNE L HOFSTETTER to Adenocarcinoma

Back to Details
This is a "connection" page, showing publications WAYNE L HOFSTETTER has written about Adenocarcinoma.
WAYNE L HOFSTETTER
Connection Strength
7.275
Adenocarcinoma
  1. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg. 2024 Feb; 117(2):320-326.
    View in: PubMed
    Score: 0.244
  2. Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Dis Esophagus. 2022 Apr 19; 35(4).
    View in: PubMed
    Score: 0.228
  3. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2021 04; 111(4):1133-1140.
    View in: PubMed
    Score: 0.204
  4. Commentary: Delayed resection for esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2020 06; 159(6):2568-2569.
    View in: PubMed
    Score: 0.194
  5. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Ann Thorac Surg. 2019 09; 108(3):845-851.
    View in: PubMed
    Score: 0.186
  6. Commentary: Maximizing response and outcomes in multimodality therapy for locally advanced esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2019 04; 157(4):1694-1695.
    View in: PubMed
    Score: 0.181
  7. Mucosal Ablation Techniques for Barrett's Esophagus and Early Esophageal Cancer. Thorac Surg Clin. 2018 Nov; 28(4):473-480.
    View in: PubMed
    Score: 0.179
  8. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018 07; 156(1):406-413.e3.
    View in: PubMed
    Score: 0.172
  9. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells. Ann Thorac Surg. 2018 Feb; 105(2):363-370.
    View in: PubMed
    Score: 0.169
  10. Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved? Eur J Radiol. 2017 Mar; 88:56-60.
    View in: PubMed
    Score: 0.158
  11. Preoperative Chemoradiation in an Era of Suboptimal Clinical Staging. JAMA Surg. 2016 Mar; 151(3):245-6.
    View in: PubMed
    Score: 0.149
  12. Preoperative Chemoradiation Therapy Versus Chemotherapy in Patients Undergoing Modified En Bloc Esophagectomy for Locally Advanced Esophageal Adenocarcinoma: Is Radiotherapy Beneficial? Ann Thorac Surg. 2016 Apr; 101(4):1262-9; discussion 1969-70.
    View in: PubMed
    Score: 0.149
  13. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016 Mar; 101(3):1075-80; Discussion 1080-1.
    View in: PubMed
    Score: 0.147
  14. Endoscopic Ultrasound Estimates for Tumor Depth at the Gastroesophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection. Ann Thorac Surg. 2015 Nov; 100(5):1812-6.
    View in: PubMed
    Score: 0.143
  15. Endoscopic management of Barrett's esophagus with high-grade dysplasia and early-stage esophageal adenocarcinoma. Thorac Surg Clin. 2013 Nov; 23(4):479-89.
    View in: PubMed
    Score: 0.127
  16. Pretreatment patient comorbidity and tobacco use increase cost and risk of postoperative complications after esophagectomy at a high-volume cancer center. J Oncol Pract. 2013 Sep; 9(5):233-9.
    View in: PubMed
    Score: 0.125
  17. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69.
    View in: PubMed
    Score: 0.123
  18. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg. 2012 Feb; 143(2):412-20.
    View in: PubMed
    Score: 0.111
  19. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1.
    View in: PubMed
    Score: 0.102
  20. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 04; 21(4):393-422.
    View in: PubMed
    Score: 0.061
  21. Localized Gastroesophageal Adenocarcinoma in the Elderly: Is Age a Factor Associated with Suboptimal Treatment? Oncology. 2023; 101(3):153-158.
    View in: PubMed
    Score: 0.059
  22. High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for Whom Surgery Should Not Be Delayed. Ann Surg. 2023 05 01; 277(5):721-726.
    View in: PubMed
    Score: 0.059
  23. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
    View in: PubMed
    Score: 0.059
  24. An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma. Ann Surg. 2022 11 01; 276(5):799-805.
    View in: PubMed
    Score: 0.058
  25. Can Clinical Response Predict Pathologic Response Following Neoadjuvant Chemoradiation for Esophageal Cancer? J Gastrointest Surg. 2022 07; 26(7):1345-1351.
    View in: PubMed
    Score: 0.057
  26. Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update. J Clin Oncol. 2021 10 01; 39(28):3182-3184.
    View in: PubMed
    Score: 0.054
  27. Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis. Ann Surg Oncol. 2021 Dec; 28(13):8485-8494.
    View in: PubMed
    Score: 0.054
  28. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study. Br J Surg. 2021 04 30; 108(4):403-411.
    View in: PubMed
    Score: 0.053
  29. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. 2021 04 01; 273(4):751-757.
    View in: PubMed
    Score: 0.053
  30. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg. 2021 Nov; 162(5):1404-1412.e2.
    View in: PubMed
    Score: 0.051
  31. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2020 08; 272(2):311-318.
    View in: PubMed
    Score: 0.051
  32. Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer. 2020 09; 23(5):904-912.
    View in: PubMed
    Score: 0.050
  33. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Ann Thorac Surg. 2020 08; 110(2):398-405.
    View in: PubMed
    Score: 0.050
  34. Ketorolac use and anastomotic leak in patients with esophageal cancer. J Thorac Cardiovasc Surg. 2021 02; 161(2):448-454.
    View in: PubMed
    Score: 0.049
  35. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech. 2019 12 17; 12(12).
    View in: PubMed
    Score: 0.049
  36. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer. 2019 11 01; 125(21):3738-3748.
    View in: PubMed
    Score: 0.047
  37. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. BMC Cancer. 2019 Jul 04; 19(1):662.
    View in: PubMed
    Score: 0.047
  38. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 07 01; 17(7):855-883.
    View in: PubMed
    Score: 0.047
  39. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295.
    View in: PubMed
    Score: 0.044
  40. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg. 2018 11; 22(11):2013-2019.
    View in: PubMed
    Score: 0.044
  41. Effects of Intraoperative Opioid Use on Recurrence-Free and Overall Survival in Patients With Esophageal Adenocarcinoma and Squamous Cell Carcinoma. Anesth Analg. 2018 07; 127(1):210-216.
    View in: PubMed
    Score: 0.044
  42. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90.
    View in: PubMed
    Score: 0.044
  43. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol. 2018 Jul; 25(7):2012-2017.
    View in: PubMed
    Score: 0.043
  44. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer. 2018 11; 21(6):1004-1013.
    View in: PubMed
    Score: 0.043
  45. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology. 2018; 94(6):345-353.
    View in: PubMed
    Score: 0.043
  46. Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer. Ann Thorac Surg. 2018 06; 105(6):1671-1677.
    View in: PubMed
    Score: 0.043
  47. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer. 2018 03 01; 124(5):998-1007.
    View in: PubMed
    Score: 0.043
  48. 18FDG-PET/CT is useful in the follow-up of surgically treated patients with oesophageal adenocarcinoma. Br J Radiol. 2018 Feb; 91(1082):20170341.
    View in: PubMed
    Score: 0.042
  49. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer. 2018 Jan; 21(1):1-9.
    View in: PubMed
    Score: 0.042
  50. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.041
  51. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer. 2018 Jan; 21(1):31-40.
    View in: PubMed
    Score: 0.041
  52. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655.
    View in: PubMed
    Score: 0.041
  53. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol. 2017 Aug; 34(8):135.
    View in: PubMed
    Score: 0.041
  54. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017 08; 124(2):318-324.
    View in: PubMed
    Score: 0.041
  55. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer. 2018 Jan; 21(1):74-83.
    View in: PubMed
    Score: 0.041
  56. 18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. J Nucl Med. 2017 11; 58(11):1756-1763.
    View in: PubMed
    Score: 0.041
  57. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25; 8(17):28696-28710.
    View in: PubMed
    Score: 0.040
  58. An age-period-cohort analysis of obesity and incident esophageal adenocarcinoma among white males. Dis Esophagus. 2017 02 01; 30(3):1-8.
    View in: PubMed
    Score: 0.040
  59. Esophageal Cancer: Associations With (pN+) Lymph Node Metastases. Ann Surg. 2017 01; 265(1):122-129.
    View in: PubMed
    Score: 0.040
  60. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016 Nov; 29(8):906-912.
    View in: PubMed
    Score: 0.039
  61. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016 Nov; 29(8):913-919.
    View in: PubMed
    Score: 0.039
  62. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016 Nov; 29(8):897-905.
    View in: PubMed
    Score: 0.039
  63. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382.
    View in: PubMed
    Score: 0.039
  64. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2017 Aug; 24(8):2291-2301.
    View in: PubMed
    Score: 0.039
  65. Final Results of NRG Oncology RTOG 0246: An?Organ-Preserving Selective Resection Strategy in?Esophageal Cancer Patients Treated with Definitive?Chemoradiation. J Thorac Oncol. 2017 02; 12(2):368-374.
    View in: PubMed
    Score: 0.039
  66. Esophagectomy Following Endoscopic Resection of Submucosal Esophageal Cancer: a Highly Curative Procedure Even with Nodal Metastases. J Gastrointest Surg. 2017 01; 21(1):62-67.
    View in: PubMed
    Score: 0.039
  67. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2017 01; 44(1):71-80.
    View in: PubMed
    Score: 0.038
  68. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer. Am J Clin Oncol. 2016 06; 39(3):228-35.
    View in: PubMed
    Score: 0.038
  69. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer. J Nucl Med. 2016 05; 57(5):691-700.
    View in: PubMed
    Score: 0.037
  70. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ? Ann Surg Oncol. 2016 Feb; 23(2):626-32.
    View in: PubMed
    Score: 0.037
  71. Can the Risk of Lymph Node Metastases Be Gauged in Endoscopically Resected Submucosal Esophageal Adenocarcinomas? A Multi-Center Study. J Gastrointest Surg. 2016 Jan; 20(1):6-12; discussion 12.
    View in: PubMed
    Score: 0.036
  72. Impact of a Fast-track Esophagectomy Protocol on Esophageal Cancer Patient Outcomes and Hospital Charges. Ann Surg. 2015 Jun; 261(6):1114-23.
    View in: PubMed
    Score: 0.035
  73. RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget. 2015 May 10; 6(13):11114-24.
    View in: PubMed
    Score: 0.035
  74. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. 2015; 89(2):65-9.
    View in: PubMed
    Score: 0.035
  75. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6.
    View in: PubMed
    Score: 0.035
  76. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 2014 Dec 01; 120(23):3635-41.
    View in: PubMed
    Score: 0.033
  77. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44.
    View in: PubMed
    Score: 0.033
  78. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6.
    View in: PubMed
    Score: 0.033
  79. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg. 2014 Sep; 98(3):1064-71.
    View in: PubMed
    Score: 0.033
  80. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9.
    View in: PubMed
    Score: 0.033
  81. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. J Clin Oncol. 2014 Jul 01; 32(19):2112-3.
    View in: PubMed
    Score: 0.033
  82. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
    View in: PubMed
    Score: 0.032
  83. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9.
    View in: PubMed
    Score: 0.032
  84. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10.
    View in: PubMed
    Score: 0.032
  85. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7.
    View in: PubMed
    Score: 0.031
  86. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg. 2013 Sep; 258(3):500-7.
    View in: PubMed
    Score: 0.031
  87. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9.
    View in: PubMed
    Score: 0.031
  88. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9.
    View in: PubMed
    Score: 0.031
  89. Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. Ann Thorac Surg. 2013 Aug; 96(2):382-90.
    View in: PubMed
    Score: 0.031
  90. Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system. J Am Coll Surg. 2013 Aug; 217(2):191-9.
    View in: PubMed
    Score: 0.031
  91. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014 Feb-Mar; 27(2):168-75.
    View in: PubMed
    Score: 0.031
  92. Loss of TGF-? adaptor ?2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res. 2013 Apr 01; 73(7):2159-69.
    View in: PubMed
    Score: 0.030
  93. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus. 2013 Sep-Oct; 26(7):708-15.
    View in: PubMed
    Score: 0.030
  94. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9.
    View in: PubMed
    Score: 0.029
  95. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg. 2012 Oct; 94(4):1126-32; discussion 1132-3.
    View in: PubMed
    Score: 0.029
  96. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
    View in: PubMed
    Score: 0.029
  97. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e345-51.
    View in: PubMed
    Score: 0.028
  98. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus. 2012 Sep-Oct; 25(7):614-22.
    View in: PubMed
    Score: 0.028
  99. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc. 2012 Feb; 75(2):242-53.
    View in: PubMed
    Score: 0.028
  100. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012 Jan; 93(1):207-12; discussion 212-3.
    View in: PubMed
    Score: 0.027
  101. Barrett's esophagus: treatments of adenocarcinomas II. Ann N Y Acad Sci. 2011 Sep; 1232:265-91.
    View in: PubMed
    Score: 0.027
  102. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):830-87.
    View in: PubMed
    Score: 0.027
  103. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol. 2011 Jul; 35(7):1045-53.
    View in: PubMed
    Score: 0.027
  104. Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3.
    View in: PubMed
    Score: 0.027
  105. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1967-72.
    View in: PubMed
    Score: 0.027
  106. Dysfunctional transforming growth factor-? signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma. Cancer. 2011 Aug 15; 117(16):3691-702.
    View in: PubMed
    Score: 0.026
  107. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):468-74.
    View in: PubMed
    Score: 0.026
  108. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer. 2010 Dec 15; 116(24):5619-27.
    View in: PubMed
    Score: 0.026
  109. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010 Nov; 252(5):744-9.
    View in: PubMed
    Score: 0.026
  110. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30.
    View in: PubMed
    Score: 0.026
  111. A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients. Ann Surg. 2010 Oct; 252(4):611-7.
    View in: PubMed
    Score: 0.026
  112. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila). 2010 Sep; 3(9):1176-86.
    View in: PubMed
    Score: 0.025
  113. Comparison between established and the Worldwide Esophageal Cancer Collaboration staging systems. Ann Thorac Surg. 2010 Jun; 89(6):1797-1803, 1804.e1-3; discussion 1803-4.
    View in: PubMed
    Score: 0.025
  114. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63.
    View in: PubMed
    Score: 0.025
  115. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15; 115(22):5184-92.
    View in: PubMed
    Score: 0.024
  116. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol. 2009 Dec; 22(12):1612-21.
    View in: PubMed
    Score: 0.024
  117. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6.
    View in: PubMed
    Score: 0.023
  118. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer. 2009 Apr 01; 115(7):1576-85.
    View in: PubMed
    Score: 0.023
  119. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009 May; 174(5):1940-8.
    View in: PubMed
    Score: 0.023
  120. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):482-9.
    View in: PubMed
    Score: 0.023
  121. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 01; 115(3):624-30.
    View in: PubMed
    Score: 0.023
  122. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus. 2009; 22(2):127-32.
    View in: PubMed
    Score: 0.023
  123. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus. 2009; 22(1):32-41.
    View in: PubMed
    Score: 0.023
  124. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer. 2008 Mar 01; 112(5):1020-7.
    View in: PubMed
    Score: 0.021
  125. Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma. Cancer. 2008 Feb 01; 112(3):503-10.
    View in: PubMed
    Score: 0.021
  126. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007 Nov; 31(11):1719-25.
    View in: PubMed
    Score: 0.021
  127. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1200-5.
    View in: PubMed
    Score: 0.020
  128. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67.
    View in: PubMed
    Score: 0.020
  129. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007 Jan 01; 109(1):125-34.
    View in: PubMed
    Score: 0.020
  130. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007 Jan; 31(1):58-64.
    View in: PubMed
    Score: 0.020
  131. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 01; 107(5):967-74.
    View in: PubMed
    Score: 0.019
  132. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006 Aug 01; 12(15):4598-604.
    View in: PubMed
    Score: 0.019
  133. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006 Mar 01; 106(5):1017-25.
    View in: PubMed
    Score: 0.019
  134. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72.
    View in: PubMed
    Score: 0.018
  135. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005 Aug; 29(8):1079-85.
    View in: PubMed
    Score: 0.018
  136. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20.
    View in: PubMed
    Score: 0.018
  137. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 02; 20(2):167-192.
    View in: PubMed
    Score: 0.014
  138. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2018 Jun; 117(8):1721-1728.
    View in: PubMed
    Score: 0.011
  139. Salvage pulmonary resection after stereotactic body radiotherapy: A feasible and safe option for local failure in selected patients. J Thorac Cardiovasc Surg. 2017 08; 154(2):689-699.
    View in: PubMed
    Score: 0.010
  140. A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. J Thorac Oncol. 2017 06; 12(6):1001-1010.
    View in: PubMed
    Score: 0.010
  141. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):885-91.
    View in: PubMed
    Score: 0.008
  142. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
    View in: PubMed
    Score: 0.007
  143. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol. 2012 May; 7(5):833-40.
    View in: PubMed
    Score: 0.007
  144. The role of PKR/eIF2a signaling pathway in prognosis of non-small cell lung cancer. PLoS One. 2011; 6(11):e24855.
    View in: PubMed
    Score: 0.007
  145. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22.
    View in: PubMed
    Score: 0.006
  146. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010 Jan; 251(1):46-50.
    View in: PubMed
    Score: 0.006
  147. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer. 2008 Sep 15; 113(6):1302-8.
    View in: PubMed
    Score: 0.006
  148. 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC). J Thorac Oncol. 2008 Sep; 3(9):979-84.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.